Daiichi Sankyo is a global pharmaceutical company on a mission to become a global top ten leader in oncology by 2030, driven by the discovery of our proprietary DXd antibody drug conjugate technology, which is poised to redefine the treatment of cancer. In Australia, we’re growing a team with a passion for innovation and compassion for patients, working with over 54 sites on 22 clinical trials evaluating our DXd ADCs and beyond, with additional studies planned. We’re committed to developing new ideas and innovations in partnership with many different healthcare stakeholders to enrich the lives of those impacted by cancer.
Source: Great Place To Work® 2024 Australia National Employee Engagement Study
Start by earning Great Place To Work-Certified™ status through the Trust Index™ employee survey and the Culture Brief. Once Certified, eligible organizations are considered for Best Workplaces™ lists during the qualification period.
Best Workplaces™ recognition is based on employee feedback collected through the Trust Index™ survey, supported by your Culture Brief submission. This keeps the focus on the real employee experience rather than marketing claims.
Eligibility starts with becoming Great Place to Work-Certified™. Your organization also needs to meet the list’s timing and participation requirements, so your results fall within the qualification window for that Best Workplaces™ list.
The Culture Brief is a short questionnaire about your organization to support your survey results. The Culture Audit goes deeper, typically asking for more detailed descriptions and evidence of your workplace practices.
